Revolution Medicines, Inc. Depreciation
Revolution Medicines, Inc. (RVMD) reported Depreciation of $2.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- Revolution Medicines, Inc. depreciation for the quarter ending 2026-06-30 was $2.10M, a 23.53% increase year-over-year.
- Revolution Medicines, Inc. depreciation for the quarter ending 2026-03-31 was $2.20M, a 37.50% increase year-over-year.
- Revolution Medicines, Inc. depreciation for the quarter ending 2025-12-31 was $2.10M, a 50.00% increase year-over-year.
- Revolution Medicines, Inc. depreciation for the quarter ending 2025-09-30 was $2.00M, a 25.00% increase year-over-year.
- Revolution Medicines, Inc. depreciation for fiscal 2025 was $7.40M, a 19.35% increase from fiscal 2024.
- Revolution Medicines, Inc. depreciation for fiscal 2024 was $6.20M, a 24.00% increase from fiscal 2023.
- Revolution Medicines, Inc. depreciation for fiscal 2023 was $5.00M, a 25.00% increase from fiscal 2022.
- Revolution Medicines, Inc. depreciation for fiscal 2022 was $4.00M, a 29.74% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.10M 10-Q · filed 2026-08-05 | $4.30M 10-Q · filed 2026-08-05 | $6.40M derived: sum of 3 quarters · filed 2026-08-05 | $8.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-06 | $4.30M derived: sum of 2 quarters · filed 2026-05-06 | $6.30M derived: sum of 3 quarters · filed 2026-05-06 | $8.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.10M derived: sum of 2 quarters · filed 2026-02-25 | $5.80M derived: sum of 3 quarters · filed 2026-08-05 | $7.40M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-05 | $3.70M derived: sum of 2 quarters · filed 2026-08-05 | $5.30M 10-Q · filed 2025-11-05 | $6.70M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $1.70M 10-Q · filed 2026-08-05 | $3.30M 10-Q · filed 2026-08-05 | $4.70M derived: sum of 3 quarters · filed 2026-08-05 | $6.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $1.60M 10-Q · filed 2026-05-06 | $3.00M derived: sum of 2 quarters · filed 2026-05-06 | $4.60M derived: sum of 3 quarters · filed 2026-05-06 | $6.20M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.00M derived: sum of 2 quarters · filed 2026-02-25 | $4.60M derived: sum of 3 quarters · filed 2026-02-25 | $6.20M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $1.60M 10-Q · filed 2025-11-05 | $3.20M derived: sum of 2 quarters · filed 2025-11-05 | $4.80M 10-Q · filed 2025-11-05 | $4.82M 10-Q · filed 2024-11-06 | $6.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $1.60M 10-Q · filed 2025-08-06 | $3.20M 10-Q · filed 2025-08-06 | $3.18M 10-Q · filed 2024-08-07 | $4.41M derived: sum of 3 quarters · filed 2026-02-25 | $5.71M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $1.50M 10-Q · filed 2025-05-07 | $1.54M 10-Q · filed 2024-05-08 | $2.81M derived: sum of 2 quarters · filed 2026-02-25 | $4.11M derived: sum of 3 quarters · filed 2026-02-25 | $5.30M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.60M derived: sum of 2 quarters · filed 2026-02-25 | $3.81M derived: sum of 3 quarters · filed 2026-02-25 | $5.00M 10-K · filed 2026-02-25 | $5.04M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $1.30M 10-Q · filed 2024-11-06 | $2.50M derived: sum of 2 quarters · filed 2024-11-06 | $3.69M 10-Q · filed 2024-11-06 | $4.88M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $1.20M 10-Q · filed 2024-08-07 | $2.43M 10-Q · filed 2024-08-07 | $2.40M 10-Q · filed 2023-08-08 | $3.58M derived: sum of 3 quarters · filed 2025-02-26 | $4.58M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2023-03-31 | $1.21M 10-Q · filed 2024-05-08 | $1.20M 10-Q · filed 2023-05-08 | $2.38M derived: sum of 2 quarters · filed 2025-02-26 | $3.38M derived: sum of 3 quarters · filed 2025-02-26 | $4.28M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2022-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.18M derived: sum of 2 quarters · filed 2025-02-26 | $3.08M derived: sum of 3 quarters · filed 2025-02-26 | $4.00M 10-K · filed 2025-02-26 | $3.97M 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $1.00M 10-Q · filed 2023-11-06 | $1.90M derived: sum of 2 quarters · filed 2023-11-06 | $2.82M 10-Q · filed 2023-11-06 | |||||
| 2022-06-30 | $900.00K 10-Q · filed 2023-08-08 | $1.80M 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $900.00K 10-Q · filed 2023-05-08 | |||||||
| 2021-12-31 | $3.08M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |